KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 96 filers reported holding KALVISTA PHARMACEUTICALS INC in Q2 2023. The put-call ratio across all filers is 1.30 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2023 | $12,580,284 | +76.3% | 1,600,545 | +51.6% | 2.47% | +76.6% |
Q4 2022 | $7,137,215 | -68.3% | 1,055,801 | -32.0% | 1.40% | -74.2% |
Q3 2022 | $22,515,000 | +49.6% | 1,551,719 | +1.4% | 5.42% | +50.1% |
Q2 2022 | $15,055,000 | +16.8% | 1,530,000 | +75.0% | 3.61% | +16.0% |
Q1 2022 | $12,886,000 | +136.4% | 874,197 | +112.2% | 3.11% | +157.1% |
Q4 2021 | $5,450,000 | – | 411,937 | – | 1.21% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,810,246 | $17,432,669 | 7.30% |
TCG Crossover Management, LLC | 3,395,495 | $32,698,617 | 4.82% |
TANG CAPITAL MANAGEMENT LLC | 3,440,345 | $33,130,522 | 4.68% |
VR Adviser, LLC | 2,916,667 | $28,087,503 | 2.96% |
Frazier Life Sciences Management, L.P. | 3,238,859 | $31,190,212 | 2.07% |
Nan Fung Group Holdings Ltd | 234,573 | $2,258,938 | 1.83% |
DAFNA Capital Management LLC | 605,532 | $5,831,273 | 1.81% |
Opaleye Management Inc. | 500,000 | $4,815,000 | 1.57% |
SILVERARC CAPITAL MANAGEMENT, LLC | 530,400 | $5,107,752 | 1.55% |
MPM BioImpact LLC | 577,958 | $5,565,736 | 1.49% |